View in EDS HTML Full Text PDF Full Text

Accelerated stem cell labeling with ferucarbotran and protamine.

Saved in:
Bibliographic Details
Title: Accelerated stem cell labeling with ferucarbotran and protamine.
Authors: Golovko DM (AUTHOR), Henning T (AUTHOR), Bauer JS (AUTHOR), Settles M (AUTHOR), Frenzel T (AUTHOR), Mayerhofer A (AUTHOR), Rummeny EJ (AUTHOR), Daldrup-Link HE (AUTHOR), Golovko, Daniel M1 (AUTHOR), Henning, Tobias (AUTHOR), Bauer, Jan S (AUTHOR), Settles, Marcus (AUTHOR), Frenzel, Thomas (AUTHOR), Mayerhofer, Artur (AUTHOR), Rummeny, Ernst J (AUTHOR), Daldrup-Link, Heike E (AUTHOR)
Source: European Radiology. Mar2010, Vol. 20 Issue 3, p640-648. 9p.
Abstract: Objective: To develop and characterize a clinically applicable, fast and efficient method for stem cell labeling with ferucarbotran and protamine for depiction with clinical MRI.Methods: The hydrodynamic diameter, zeta potential and relaxivities of ferucarbotran and varying concentrations of protamine were measured. Once the optimized ratio was found, human mesenchymal stem cells (MSCs) were labeled at varying incubation times (1-24 h). Viability was assessed via Trypan blue exclusion testing. 150,000 labeled cells in Ficoll solution were imaged with T1-, T2- and T2*-weighted sequences at 3 T, and relaxation rates were calculated.Results: Varying the concentrations of protamine allows for easy modification of the physicochemical properties. Simple incubation with ferucarbotran alone resulted in efficient labeling after 24 h of incubation while assisted labeling with protamine resulted in similar results after only 1 h. Cell viability remained unaffected. R2 and R2* relaxation rates were drastically increased. Electron microscopy confirmed intracellular iron oxide uptake in lysosomes. Relaxation times correlated with results from ICP-AES.Conclusion: Our results show internalization of ferucarbotran can be accelerated in MSCs with protamine, an approved heparin antagonist and potentially clinically applicable uptake-enhancing agent. [ABSTRACT FROM AUTHOR]
Copyright of European Radiology is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Engineering Source
Full text is not displayed to guests.
Description
Abstract:<bold>Objective: </bold>To develop and characterize a clinically applicable, fast and efficient method for stem cell labeling with ferucarbotran and protamine for depiction with clinical MRI.<bold>Methods: </bold>The hydrodynamic diameter, zeta potential and relaxivities of ferucarbotran and varying concentrations of protamine were measured. Once the optimized ratio was found, human mesenchymal stem cells (MSCs) were labeled at varying incubation times (1-24 h). Viability was assessed via Trypan blue exclusion testing. 150,000 labeled cells in Ficoll solution were imaged with T1-, T2- and T2*-weighted sequences at 3 T, and relaxation rates were calculated.<bold>Results: </bold>Varying the concentrations of protamine allows for easy modification of the physicochemical properties. Simple incubation with ferucarbotran alone resulted in efficient labeling after 24 h of incubation while assisted labeling with protamine resulted in similar results after only 1 h. Cell viability remained unaffected. R2 and R2* relaxation rates were drastically increased. Electron microscopy confirmed intracellular iron oxide uptake in lysosomes. Relaxation times correlated with results from ICP-AES.<bold>Conclusion: </bold>Our results show internalization of ferucarbotran can be accelerated in MSCs with protamine, an approved heparin antagonist and potentially clinically applicable uptake-enhancing agent. [ABSTRACT FROM AUTHOR]
ISSN:09387994
DOI:10.1007/s00330-009-1585-1